Brief: Paxmedica, Inc. Provides First Quarter 2023 Business Update Phase 3 Hat-301 Top Line Results Expected In Second Half 2023
15/05/2023 22:28
PaxMedica Inc PXMD.O :
* PAXMEDICA, INC. PROVIDES FIRST QUARTER 2023 BUSINESS
UPDATE;
PHASE 3 HAT-301 TOP LINE RESULTS EXPECTED IN SECOND HALF 2023
* PAXMEDICA INC- AS OF MARCH 31, 2023, PAXMEDICA HAD $3.9
MILLION
IN CASH
Source text for Eikon: ID:nGNX4JyDVl
Further company coverage: PXMD.O
Recent news on Kuvatris Therapeutics
See all newsBrief: PaxMedica Responds To Emergency Request For IV Suramin And Commits To Provide Immediate Access To PAX-101
PaxMedica rises on Malawi's request for access to sleeping sickness drug
Brief: Paxmedica Receives Emergency Request For Iv Suramin From African Health Ministry For Use In Treating Fatal Sleeping Sickness
Brief: PaxMedica Achieves Key Milestone In The Development Of PAX-101 And Provides Update On Potential NDA Submission
Brief: Paxmedica Announces Pricing Of $7.0 Million Public Offering